31 results about "Rosiglitazona" patented technology

The invention discloses a rogridone hapten as well as a corresponding artificial antigen and an antibody thereof. The invention also discloses a preparation method and an application for the rogridone hapten as well as the corresponding artificial antigen and the antibody. The method comprises the following steps: adopting rogridone as a raw material which reacts with halogenated benzyl benzoate to generate the carboxyl-contained rogridone hapten; then, coupling the rogridone hapten and protein by an activated fat method or a mixed acid anhydride method to prepare the rogridone artificial antigen; and using the rogridone artificial antigen to immunize animals so as to generate the high-specificity rogridone antibody. An immunodetection method for the rogridone antibody and the rogridone artificial antigen can be applied to the on-site rapid detection of the rogridone and has an important realistic meaning to realize the rapid detection of the health food safety.

The invention belongs to the technical field of weight-loss drugs, and provides a pharmaceutical composition with a fat-reducing effect, including a photosensitizer and rosiglitazone; wherein the photosensitizer includes photoporphyrin, verteporfin, temoporfin, One of chlorin e6, zinc phthalocyanine, and 5-aminolevulinic acid or a mixture of them; the mass ratio of the photosensitizer to rosiglitazone is 3:1-10:1. During administration, the pharmaceutical composition powder of the present invention is diluted and dissolved with physiological saline, and then administered through intravenous injection. The present invention combines the photodynamic cell killing of the photosensitizer with the browning induction of rosiglitazone to realize the optimal weight loss strategy combining "fast-slow" and "local-whole". The two drugs are a good complementary pair, and the experimental results show that they have quite good synergistic effects; in addition, rosiglitazone also has a significant inhibitory effect on the adverse reactions that may be caused by photosensitizer treatment.

The invention discloses an application of a rosiglitazone nano preparation in treating vascular restenosis. A rosiglitazone composition contains rosiglitazone, a polylactic acid-polyglycolic acid copolymer, lecithin and distearyl phosphatidyl ethanolamine-polyethylene glycol 2000. A rosiglitazone nano preparation is nano particles formed by rosiglitazone, polylactic acid-polyglycolic acid copolymer, lecithin and distearyl phosphatidyl ethanolamine-polyethylene glycol 2000, the structure is of a spherical structure, and the particle size is between 250 nm and 300 nm. The invention also discloses a preparation method of the rosiglitazone nano preparation, and the rosiglitazone nano preparation can effectively treat vascular restenosis after implanting of an intravascular stent, and can reduce the toxicity of rosiglitazone and improve the biological safety.

The invention discloses a saccharin salt of rosiglitazone and a preparation method thereof. This rosiglitazone saccharin salt contains rosiglitazone cation and saccharin anion in a molar ratio of 1:1. At the same time, the preparation method of the rosiglitazone saccharin salt is also disclosed. The rosiglitazone saccharin salt is reacted in a solvent, and the rosiglitazone saccharin salt is obtained by stirring, ultrasonication, volatilization or cooling crystallization. The present invention provides a brand-new rosiglitazone saccharin salt, which has obvious advantages in the dissolution property and taste improvement of the drug, and can be applied in the pharmaceutical industry, and the preparation method is simple and the crystallization process is simple. Easy to control, good reproducibility, suitable for industrial production.

The invention discloses a qualitative analysis detection method for illegally mixed high-polar chemical anti-diabetic components in anti-diabetic traditional Chinese medicine products. The method comprises the following steps that: 1) high efficient liquid phase chromatography conditions: an ammonium acetate-triethylamine-acetonitrile moving phase system and a C18 chromatographic column with certain specification are used, the wavelength is detected by ultraviolet, and the flow rate is 1.0ml / min; 2) analysis result: glibenclamide, glipizide, gliclazide, glimepiride, gliquidone, repaglinide, nateglinide, rosiglitazone and pioglitazone hydrochloride can realize the complete separation; 3) result judgment: when retention time of a chromatographic peak in an anti-diabetic traditional Chinese medicine product is consistent with that of anti-diabetic medicine in the step 2) and the apparent absorption is shown out, which indicate that the anti-diabetic medicine is contained in the sample tobe tested. The method has the advantages of quickness, simplicity, convenience, high sensitivity, strong specialization, broad coverage and so on.

The invention discloses a rosiglitazone gentisate and a preparation method thereof. This rosiglitazone gentisate contains rosiglitazone cation and gentisic acid anion in a molar ratio of 1:1. At the same time, the preparation method of the rosiglitazone gentisate is also disclosed. The present invention converts rosiglitazone into a brand-new rosiglitazone gentisate for the first time, and the rosiglitazone gentisate has a faster dissolution rate and a larger surface area than rosiglitazone free base. The apparent solubility is conducive to improving the bioavailability of rosiglitazone. In addition, the preparation method of rosiglitazone gentisate disclosed in the present invention has simple process, easy control of the crystallization process, good reproducibility, and is suitable for industrial production.

The invention discloses a preparation method and application of a PHBV / rosiglitazone sustained-release film, which belongs to the technical field of medicine. After mixing PHBV powder, chloroform and dimethylformamide, it is configured into a PHBV with a mass-volume ratio of 5%. ‑TCM / DMF silk solution for use. Rosiglitazone was dissolved in dimethyl sulfoxide solution to prepare RSG / DMSO solutions with different concentration gradients. Add it into the spinning solution, configure the spinning solution with different final concentrations, transfer it into a glass syringe, and perform electrospinning to form a rosiglitazone / PHBV slow-release film, which is used in anti-glaucoma filtration surgery. It is safe and It has very important clinical significance to effectively and durably prevent scar formation after glaucoma surgery and improve the long-term success rate of glaucoma surgery.

The invention relates to a rosiglitazone analogue, a preparation method and application thereof. Described compound has the structure shown in following formula (I), R 1 represents C that is unsubstituted or optionally substituted by 3‑10 Cycloalkyl: halogen, nitro, cyano, hydroxyl, mercapto, C 1‑6 Alkyl, C 1‑6 Alkoxy, halo C 1‑6 Alkyl; A 1 、A 2 The same or different, independently of each other represents C that is unsubstituted or optionally substituted by 6‑14 Aryl or 5‑14 membered heteroaryl: halogen, nitro, cyano, hydroxyl, mercapto, C 1‑6 Alkyl, C 1‑6 Alkoxy, halo C 1‑6 Alkyl; n is an integer of 0-5; R 2 means H or C 1‑6 Alkyl; R 3 Represents H; X, Z, W are the same or different, and independently represent S or O; represent a single bond or a double bond, and when it is a single bond, there is R 3 ; When double bond, R is absent 3 . The invention also provides its preparation method and its application in the preparation of medicines for treating or preventing diabetes.